Immunomedics developed Trodelvy, an antibody-drug conjugate used to treat triple-negative breast cancer.
Gilead expects the deal to immediately bolster its revenue growth, and for it to be neutral to accretive to adjusted earnings per share in 2023, as well as"significantly accretive thereafter," Gilead said. Over the years, Gilead has received enormous pressure from investors to put its massive cash pile to work. At the end of 2018, Gilead had $30 billion in cash and short-term equivalents, according to data from YCharts.com.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more: